Trial Profile
Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in Restless Legs Syndrome Patients With Iron-deficiency Anemia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 16 Sep 2022
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Restless legs syndrome
- Focus Therapeutic Use
- Sponsors American Regent
- 22 Aug 2022 Status changed to discontinued.
- 19 Mar 2021 Planned End Date changed from 1 Dec 2021 to 30 Jun 2022.
- 19 Mar 2021 Planned primary completion date changed from 1 Mar 2021 to 30 Jun 2021.